MarketBeat
09 May 2026, 04:08 UTC · 19w ago
Verdict
Headline takes no side. We score TMCI −0.20 across six claims — slightly bearish.
−0.20slightly bearish
More negative than 68% of ticker scores this week
What the story claims
6 claims · scored −1 bearish … +1 bullish
Treace reaffirmed its full-year 2026 revenue guidance of $202 million to $212 million, representing a decline of 5% to flat, and expects revenue declines to continue until the fourth quarter.
So whatReaffirming guidance provides a critical anchor for valuation models amid ongoing revenue declines, giving investors near-term clarity on the expected stabilization timeline.
More positive than 97% of claims this week
A revenue mix shift toward lower-priced minimally invasive products drove a 10% year-over-year revenue decline to $47.2 million and is expected to pressure average selling prices until the third quarter.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More negative than 95% of claims this week
About 35% of Treace's Lapiplasty surgeon user base had incorporated at least one of the three new bunion systems, up from 25% in the fourth quarter of 2025, and 30% of new surgeons also adopted Lapiplasty technology.
More positive than 85% of claims this week
New products including SuperBite and SpeedXM are expected to begin full commercialization in the third quarter, collectively expanding the total addressable market by approximately $300 million and targeting higher ASP midfoot and hindfoot procedures.
So whatExpanding TAM by $300 million and introducing higher-ASP products provides a clear pathway to offset current mix headwinds and accelerate growth in late 2026.
More positive than 83% of claims this week
Which stocks this story touches
More negative than 68% of ticker scores this week
The company reported a revenue decline, a net loss, and a widened EBITDA loss, though it reaffirmed its full-year outlook and highlighted new product adoption.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+122.9%
Price is moving against the score
$4.48 vs $2.01 close before publication (May 8) · not market-adjusted
TMCI chart →
